Drug Makers Focusing on Pain Management Alternatives to Opioid Drugs

Drug Makers Focusing on Pain Management Alternatives to Opioid Drugs

Publication date: Feb 14, 2020

PALM BEACH, Florida, Feb. 13, 2020 /PRNewswire/ — Opioid drugs are and have been a God-send for many patients whose severe, excruciating pain had no other drug or device to allow them to escape from its throes. .. But we all know that the other side of that coin has created a social hell of its own.

That is the impetus for the ever increasing non-opioid pain, treatment and device markets efforts to find alternatives and effective replacements for opioids.

Active biotech and pharma companies in the markets this week include: Q BioMed Inc. (otcqb:QBIO), Collegium Pharmaceutical, Inc.

Q BioMed Inc. (otcqb:QBIO) BREAKING NEWS: Q BioMed Launches Non-Opioid Treatment for Metastatic Bone Pain – Q BioMed a commercial stage biotech company, announced today the launch of its FDA approved non-opioid drug Strontium89 (Strontium Chloride Sr-89 Injection, USP), which has been shown in clinical studies to help relieve persistent pain associated with cancer that has metastasized to bone.

In several multicenter, placebo-controlled trials in cancer patients with persistent pain after external beam radiation therapy for bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo, with a greater percentage of patients experiencing pain scores of zero without any need for opioid or non-opioid rescue analgesics.

Due to the opioid crisis, clinicians and patients are looking for pain management alternatives.

Strontium89, which is administered every 3 months, has been shown to relieve pain in over 70% of patients who received the treatment.

We look forward to being able to help serve the unmet needs of the millions of patients suffering from debilitating bone pain associated with metastatic cancer.

Years of well-documented data show that Strontium89 can help alleviate the pain suffered by most patients with painful bone metastases.

We believe this drug has a very important role to play as clinicians move toward proven non-opioid therapeutics for pain palliation,” stated Q BioMed CEO Denis Corin.

COLL, -0. 62%, a specialty pharmaceutical company committed to being the leader in responsible pain management, recently announced that it has entered into a definitive agreement to acquire the U. S. rights to the Nucynta Franchise from Assertio Therapeutics, Inc. (“Assertio”) for $375. 0 million in cash.

Mallinckrodt plc MNK, -7. 50% a global biopharmaceutical company, recently confirmed enrollment of the first patient in the company’s Phase 4, multi-center, multiple-dose, open-label study to assess the effects of Acthar Gel as a therapy option in patients with severe keratitis.

“I am pleased that the first patient has been enrolled in this important Phase 4 study, the results of which may potentially provide data to further support Acthar Gel as a treatment option in appropriate keratitis patients. “

Teva Pharmaceutical Industries Limited TEVA, -6. 54% recently announced positive results from two Phase 2/3 trials evaluating AJOVY(R) (fremanezumab) in patients in Japan.

Concepts Keywords
Acthar Mallinckrodt
Addiction Radiation
Allergan Endo International plc
Analgesics Morphinans
Biopharmaceutical Perception
Biotech Pain
Blood Platelets Psychoactive drugs
Bone Opioids
Bone Marrow Morphine
Broker Dealer RTT
Cancer Pain management
CEO Radiation therapy
Chief Executive Officer Painful bone metastases
Contract Manufacturing Considerable severe keratitis
Criminal Justice Chronic acute pain
Diabetes Cancer
Disability Pain related disorders
EBITDA Insurance
Endo International Biopharmaceutical
FDA
Florida
God
Headache
Healthcare
Hospital
Indicative
Insurance
Japan
Keratitis
Mallinckrodt
Medicare
Metastasized
Metastatic Cancer
Migraine
National Emergency
Ophthalmology
Opioid
Opioid Addiction
Opioid Epidemic
Opioid Overdose
Opioids
Otcqb
Otsuka Pharmaceutical
Pain
Pain Management
Palliation
PALM BEACH
Par Pharmaceutical
Pharma
Pharmaceutical Company
Physical Activity
Placebo
President
Safe Harbor
Securities
Securities Exchange Commission
Sr 89
Teva
TEVA
Toxicity
USD
USP
Vice President

Semantics

Type Source Name
drug DRUGBANK Coenzyme M
disease MESH lifestyle
disease MESH growth
disease MESH Drug Abuse
disease MESH opioid addiction
disease MESH Migraine
drug DRUGBANK Methylphenidate
drug DRUGBANK Fremanezumab
drug DRUGBANK Sucralfate
disease MESH keratitis
drug DRUGBANK Corticotropin
drug DRUGBANK Tapentadol
disease MESH suffering
disease MESH metastases
drug DRUGBANK Tricyclazole
drug DRUGBANK Strontium chloride Sr-89
drug DRUGBANK Nonoxynol-9
disease MESH heart diseases
disease MESH cancer
disease MESH emergency

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *